Our global facilities are configured with the necessary controls required for the handling and processing of highly potent molecules and we offer our customers a complete, global end-to-end development solution from early-phase formulation screening through clinical and commercial manufacturing.
Highly potent active pharmaceutical ingredients (HPAPIs) are becoming increasingly common in drug development pipelines. This is especially true in the oncology sector for example, as researchers look for therapies that have greater selectivity and pharmacological activity.
HPAPIs present an array of additional CMC challenges, mainly due to the containment requirements that protect both the operators and manufacturing facilities. HPAPIs production processes usually also require a greater level of precision and control due to the very small quantities of drug present in the final dosage form.
Using Quotient Sciences experience and expertise across the industry drug development pipeline, we have actively responded to the challenges associated with the manufacturing of today’s high-potency drug products. We have ensured and invested in our state-of-the-art facilities so that they are capable of handling compounds with a maximum performance-based level of exposure classification for our customers.
If you have any questions relating to how we handle HPAPIs please don't hesitate to bet in touch wioth our team of scientific experts who will be happy to assist you with your highly-potent drug development challenges.